The Chikungunya virus is transmitted to humans via infected mosquitoes and causes large outbreaks with high attack rates. With outbreaks in Africa, America, Asia, Europe, and islands in the Indian and Pacific Oceans, the Chikungunya virus is posing a growing risk to citizens and travelers in infected regions of the world. Still no vaccine or preventive drug is available and annual sales for an efficient vaccine are expected to exceed 300 Million USD annually. Themis’ Chikungunya vaccine candidate already demonstrated its excellent immunogenicity profile as well as its safety and tolerability in a phase I clinical trial. Results showing clear dose responses were published in the ‘The Lancet Infectious Diseases’ in 2015. The further clinical development is currently progressing and market approval is expected within the next 2 to 3 years. The program is currently in Phase 2 clinical studies in 600 patients across the US, EU and South and Central America with read-out expected in 2018.

More information on the ongoing Phase 2 studies can be found on